Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Pawan Bali"'
Autor:
Ersin Gümüş, Diclehan Orhan, Michael S. Hershfield, Aysel Yüce, Saliha Esenboga, Togay Yılmaz, Ilhan Tezcan, Duygu Uçkan Çetinkaya, Pawan Bali, Kaan Boztug, Tuba Turul Ozgur, Cagman Tan, Baris Kuskonmaz, Pınar Gur Cetinkaya, Deniz Cagdas, Ines Santisteban, Safa Baris, Ozden Sanal, Betul Karaatmaca
Publikováno v:
Journal of Clinical Immunology. 38:484-493
Adenosine deaminase (ADA) deficiency is an autosomal recessive primary immunodeficiency. It results in the intracellular accumulation of toxic metabolites which have effects particularly on lymphocytes and the brain. The aim of this study was to eval
Autor:
Elke Lainka, Michael S. Hershfield, W. Friedrich, Ines Santisteban, Pawan Bali, Annette Seibt, Jennifer Neubert, Tim Niehues
Publikováno v:
Clinical and Vaccine Immunology. 12:861-866
We describe the effects of polyethylene glycol-conjugated adenosine deaminase (ADA) replacement therapy on lymphocyte counts, activation, apoptosis, proliferation, and cytokine secretion in a 14-month-old girl with “delayed-onset” ADA deficiency
Autor:
Michael Loubser, Abdulaziz Al-Ghonaium, Eva Richard, Michael S. Hershfield, Pawan Bali, Majed Koleilat, Francisco X. Arredondo-Vega, Mariam Al-Helali, Ines Santisteban
Publikováno v:
Blood. 99:1005-1013
Four patients from 3 Saudi Arabian families had delayed onset of immune deficiency due to homozygosity for a novel intronic mutation, g.31701T>A, in the last splice acceptor site of the adenosine deaminase (ADA) gene. Aberrant splicing mutated the la
Autor:
Erwin W. Gelfand, Ines Santisteban, Jordan K. Abbott, Michael S. Hershfield, Divya Jayaraman, Pawan Bali
Publikováno v:
Journal of Allergy and Clinical Immunology. 139:AB112
Autor:
Shunichi Kato, Yukio Sakiyama, Tadashi Ariga, Ryoji Kobayashi, Nobuaki Kawamura, Shunichiro Takezaki, Yuka Okura, F. Tsuchida, Norikazu Hatano, Miyuki Kida, Michael S. Hershfield, Nariaki Toita, Yoshihiro Maeyama, Makoto Otsu, Osamu Tatsuzawa, Fabio Candotti, Masanari Kitagawa, Satoru Nakajima, Masafumi Onodera, Junichi Mineno, Yoshinori Matsumoto, Masafumi Yamada, Pawan Bali
Publikováno v:
Journal of clinical immunology. 35(4)
Objective We here describe treatment outcomes in two adenosine deaminase (ADA)-deficiency patients (pt) who received stem cell gene therapy (SCGT) with no cytoreductive conditioning. As this protocol has features distinct from those of other clinical
Autor:
John S. Barber, Joshua D. Milner, Elizabeth Garabedian, Nina Jones, Robert A. Sokolic, Kelly D. Stone, Avanti Desai, Pawan Bali, Fabio Candotti, Monica G. Lawrence, Michael S. Hershfield, Michelle O'Brien
Publikováno v:
The Journal of allergy and clinical immunology. 132(6)
Autor:
Pawan Bali, Michael Schlesier, Elisabeth Wiech, Jörn Oliver Sass, Paul Fisch, Giancarlo la Marca, Ines Santisteban, Stephan Borte, Klaus Schwarz, Michael S. Hershfield, Kerstin Felgentreff, Carla Neumann, Bernd Buchholz, Stephan Ehl, Carsten Speckmann, Bodo Grimbacher
Publikováno v:
The Journal of allergy and clinical immunology. 130(4)
Autor:
Naynesh Kamani, Robert A. Sokolic, I. Celine Hanson, Irina Maric, Kit L. Shaw, Rebecca H. Buckley, Pawan Bali, Andrew C. Issekutz, Fabio Candotti, Alan S. Wayne, Chimene Kesserwan, Michael S. Hershfield, Margaret Dodds, Donald B. Kohn, Elizabeth Garabedian, Ben Tan
Publikováno v:
Blood. 118(10)
Genetic deficiency of adenosine deaminase (ADA) can cause profound lymphopenia and result in the clinical presentation of severe combined immune deficiency (SCID). However, because of the ubiquitous expression of ADA, ADA-deficient patients often pre
Autor:
Osamu Tatsuzawa, Norikazu Hatano, Nariaki Toita, Fabio Candotti, Masafumi Onodera, Satoru Nakajima, Makoto Otsu, Tadashi Ariga, Michael S. Hershfield, Nobuaki Kawamura, Yukio Sakiyama, Miyuki Kida, Ryouji Kobayashi, Yoshihiro Maeyama, Pawan Bali
Publikováno v:
Molecular Therapy. 13:S418
In the previous meeting, we reported the initial follow-up of the two patients with adenosine deaminase (ADA)-deficiency whom we had treated in a clinical trial of retroviral-mediated stem cell gene therapy (SCGT). Our protocol is unique in that pati